Cooley's Anemia Symposium 2022

Efficacy and Safety of Betibeglogene Autotemcel (beti-cel) Gene Therapy in 63 Patients with Transfusion-Dependent β-Thalassemia (TDT): 7-Year Post-Infusion Follow-up of Phase 1/2 and Phase 3 Studies

Janet L. Kwiatkowski[1]; Franco Locatelli[2]; Jennifer Schneiderman[3]; Alexis A. Thompson[4]; John B. Porter[5]; Suradej Hongeng[6]; Andreas E. Kulozik[7]; Marina Cavazzana[8]; Martin G. Sauer[9]; Adrian J. Thrasher[10]; Isabelle Thuret[11]; Ashutosh Lal[12]; John E.J. Rasko[13]; Evangelia Yannaki[14]; Katiana Gruppioni[15]; Richard A. Colvin[15]; Mark C. Walters[12]

[1]Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; [2]IRCCS Ospedale Pediatrico Bambino Gesù, Sapienza, University of Rome, Rome, Italy; [3]Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; [4]Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA (current affiliation: Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA); [5]University College London Hospital, London, UK; [6]Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; [7]Molecular Medicine Partnership Unit (MMPU), European Molecular Biology Laboratory (EMBL), and Department of Pediatric Oncology, Hematology, and Immunology, University of Heidelberg, Heidelberg, Germany; [8]Biotherapy Department and Clinical Investigation Center, Assistance Publique Hopitaux de Paris, Inserm, Paris, France; Université de Paris, Paris, France; Imagine Institute, Paris, France; [9]Department of Pediatric Hematology/Oncology and Blood Stem Cell Transplantation, Hannover Medical School, Hannover, Germany; [10]UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital NHS Trust, London, UK; [11]Hôpital de la Timone, Marseille, France; [12]University of California San Francisco Benioff Children's Hospital, Oakland, CA, USA; [13]The University of Sydney, Sydney, Australia; Centenary Institute, Camperdown, Australia; Cell and Molecular Therapies, Royal Prince Alfred Hospital, Camperdown, Australia; [14]Gene and Cell Therapy Center, Hematology-HCT Unit, G. Papanikolaou Hospital, Thessaloniki, Greece; [15]bluebird bio, Inc., Somerville, MA, USA

Disclosures

Dr. Kwiatkowski has been a consultant for Agios, bluebird bio, Biomarin, Bristol Myers Squibb, Chiesi, Celgene, Imara, Forma, and Silence Therapeutics and received research funding from Apopharma, Bioverativ, bluebird bio, Imara, Forma, and Sangamo.

beti-cel gene therapy is a one-time treatment option for patients with TDT

- TDT is a severe, genetic disease caused by mutations in the *HBB* gene encoding β-globin
  - β-globin mutations result in absent or significantly reduced HbA, which normally accounts for ~95% of total Hb in blood after 6 months of age[1,2]
  - Results in lifelong dependence on regular transfusions, which leads to iron overload and associated complications and comorbidities
- Autologous gene therapy with beti-cel aims to establish lifelong, functional HbA allowing for transfusion independence
- beti-cel is US FDA-approved for the treatment of adult and pediatric patients with β-thalassemia who require regular red blood cell transfusions

Patients treated with beti-cel gene therapy



N = 63 patients treated with beti-cel

n = 57 enrolled in long term follow-up study (LTF-303)

Follow-up after beti-cel infusion, median months (min–max):

All Patients (N=63)	41.4 (9.0–87.5)
Phase 1/2 (N=22)	72.0 (59.9–87.5)
Phase 3 (N=41)	32.9 (9.0–53.7)

HbA, adult hemoglobin; HRQoL, health-related quality of life; PedsQL, Pediatric Quality of Life Inventory; SF-36v, Short Form-36 Health Survey Physical Component Summary and Mental Component Summary; TDT, transfusion-dependent β-thalassemia.

1. Paramore et al. Patient. 2021;14:197-208. 2. Thomas et al. Critical Care & Pain. 2012;12:251-6.

Data as of August 18, 2021

beti-cel adds copies of a modified *HBB* gene into patients' HSCs through transduction of autologous CD34+ cells with BB305 lentiviral vector

HSC collection
Mobilization (G-CSF + plerixafor) and apheresis

Busulfan myeloablative conditioning

beti-cel IV infusion

Transduced HSCs engraft and reconstitute RBCs which contain HbA^{T87Q}



Drug product centralized manufacturing



Select CD34+ cells

HSCs transduced with BB305 lentiviral vector (encodes for $\beta^{A\text{-}T87Q}$-globin)

Cryopreserve, test, release drug product



2-year follow-up on parent study

13-year long-term follow-up study

HbA^{T87Q}
Gene therapy-derived functional HbA



beti-cel–derived HbA^{T87Q} has oxygen affinity similar to that of endogenous HbA^{1}

G-CSF, granulocyte colony-stimulating factor; HbA, adult hemoglobin; HSC, hematopoietic stem cell; IV, intravenous; RBC, red blood cell.

1. Pawliuk R, et al. *Science.* 2001;294(5550):2368-71.

Optimized manufacturing resulted in improved beti-cel drug product characteristics in Phase 3 studies

		Phase 1/2 (N = 22)	Phase 3 (N = 41)
Baseline patient characteristics			
Genotype, n (%)	non-β^0/β^0	**14** (64)	**29** (71)
	β^0/β^0	**8** (36)	**12** (29)
Age at consent, median (min – max), years		**20** (12 – 35)	**13** (4 – 34)
Liver iron concentration, median (min – max), mg Fe/g dw		**7.1** (0.4 – 26.4)	**4.9** (1.0 – 41.0)
Cardiac T2*, median (min – max), msec		**34** (10 – 54)	**37** (15 – 75)
Splenectomy, n (%)		**9** (41)	**7** (17.1)
Fertility preservation[a], n (%)		**13** (59.1)	**30** (73.2)

	Phase 1/2 (N = 22)	Phase 3 (N = 41)
Drug product (average per patient)		
Vector copy number median (min – max), c/dg	**0.8** (0.3 – 2.1)	**3.0** (1.2 – 7.0)
$CD34^+$ cells transduced median (min – max), %	**32**[‡] (17 – 58)	**78** (34 – 94)
Cell dose median (min – max), x 10^6 $CD34^+$ cells/kg	**8.9** (5.2 – 18.1)	**9.4** (5.0 – 42.1)
Busulfan Conditioning		
Estimated daily average AUC over 4 days median (min – max), µM*min	**4175** (3030 – 5212)	**4310** (3605 – 9086)

In phase 3 studies, busulfan washout levels 48 hours after 4 days of conditioning were <125 ng/ml in all patients.[b]

AUC, area under the curve; c/dg, copies per diploid genome; Fe/g dw, iron content per gram dry weight.

[a] Fertility preservation was an optional procedure; [‡]N=18; not evaluated in HGB-205. [b] Busulfan testing not available for one patient.

Data as of August 18, 2021

Patient demographics by study

		HGB-204 (N = 18)	HGB-205 (N = 4)	HGB-207 (N = 23)	HGB-212 (N = 18)	All Studies (N=63)
Baseline patient characteristics						
Genotype, n (%)	non-β^0/β^0	**10** (56)	**4** (100)	**23** (100)	**6** (33)	**43** (68)
	β^0/β^0	**8** (44)	**0**	**0**	**12** (67)	**20** (32)
Age at consent, median (min–max), years		**20** (12 – 35)	**18** (16 – 19)	**15** (4 – 34)	**13** (4 – 33)	**17** (4 – 35)
Pre-study pRBC transfusion volume, [†] annualized median, mL/kg/year		**171.2** (124 – 273)		**207.9** (142 – 274)	**194** (75 – 289)	-
Number of pre-study pRBC transfusions, [†] n/year		**13.0** (10.0 – 17.5)		**16.0** (11.5 – 37.0)	**17.3** (11.0 – 39.5)	-
Liver iron concentration, median (min–max), mg Fe/g dw		**5.7** (0.4 – 26.4)	**11.2** (3.9 – 14.0)	**5.3** (1.0 – 41.0)	**3.6** (1.2 – 13.2)	**5.3** (0.4 – 41.0)
Cardiac T2*, median (min–max), msec		**35** (10 – 54)	**33** (29 – 46)	**37** (21 – 57)	**37** (15 – 75)	**36** (10 – 75)
Splenectomy, n (%)		**6** (33)	**3** (75)	**4** (17)	**3** (17)	**16** (25)
Fertility preservation, n (%) [‡]		**9** (50)	**4** (100)	**15** (65)	**15** (65)	**43** (68)

Fe/g dw, iron content per gram dry weight.

[†] Data as of 12 June 2019 for Phase 1/2 and 9 March 2021 for HGB-207 and HGB-212. [‡] Fertility preservation was an optional procedure.

Persistent vector-positive cells and durable HbA^{T87Q} levels support stable total Hb

Peripheral blood vector copy number

Median PB VCN in Phase 3: 1.2 c/dg at M12 and 1.0 c/dg at M24



n =	39	39	35	35	17			
n =	22	22	21	22	22	22	19	14

Total unsupported Hb and gene therapy-derived HbA^{T87Q}

Median total Hb in Phase 3: 11.1 g/dL at M12 and 11.3g/dl at M24



Total Hb n =	39	36	31	31	18			
HbA^{T87Q} n =	37	39	35	35	17			
Total Hb n =	13	17	18	18	19	19	18	14
HbA^{T87Q} n =	22	22	21	22	22	22	17	14

c/dg, copies per diploid genome; Hb, hemoglobin; PB VCN, peripheral blood vector copy number.
Median (Q1 – Q3) depicted. Unsupported Hb is defined as no prior pRBC transfusion in the prior 60 days.

Phase 3 studies: maintenance of TI for up to 4 years of follow-up



	Phase 3 (N=41)	Phase 1/2 (N=22)
TI-evaluable patients who completed the study and achieved TI, % (n/N)	89.5 (34/38)	68.2 (15/22)
Patients who achieved and remained TI, %	100	100
Duration of TI, median (min – max), months	31.6 (13.3 –49.1)	65.9 (19.8 – 84.5)
Weighted average Hb during TI, median (min – max), g/dL	11.3 (9.5 – 13.7)	10.3 (9.1 – 13.2)

*Patient's total Hb level at Month 22 was 13.4 g/dL. After a planned orthopedic surgery, the patient had blood loss, which required 1 packed red blood cell transfusion.

Hb, hemoglobin; TI, transfusion independence (defined as weighted average Hb ≥ 9 g/dL without packed red blood cell transfusions for ≥ 12 months).
Red dots depict transfusion episode. Black dotted line denotes completion of parent study and enrollment in LTF-303.

Hematopoietic recovery after beti-cel infusion

Engraftment and hospitalization
(pooled Phase 1/2 and Phase 3)

Time to event post-infusion, median (min – max), days	N=63*
Neutrophil engraftment ANC ≥500 cells/μL x 3 days	**23** (13 – 39)
Platelet engraftment ≥20,000 platelets/μL x 3 days	**45** (19 – 191†)
Duration of hospitalization‡	**43** (27 – 92)
Phase 1/2	**40** (27 – 69)
Phase 3	**44** (29 – 92)

Lymphocyte subsets generally within normal range after beti-cel#

CD3- CD16+ CD56+ NK cells



CD19+ B-cells



CD4+ T-cells



CD8+ T-cells



ANC, absolute neutrophil count; NK, natural killer.

* Patients from Phase 1/2 (n=22) and Phase 3 (n=41) studies were pooled. † One patient achieved neutrophil engraftment on day 24 but did not achieve platelet engraftment until day 191.

‡ Defined as the time from admission for conditioning through post-infusion discharge. # Median (Q1, Q3) depicted; grey bars indicate normal range.

Improved erythropoiesis in patients who achieved TI

Soluble transferrin receptor



n =	11	11	12	10	4	8	1
n =	34	30	31	7			

Reticulocyte count



n =	15	14	15	15	15	15	10	3
n =	33	32	29	18	2			

Erythropoietin*



n =	29	29	27	9

EPO, erythropoietin; sTfR, soluble transferrin receptor; TI, transfusion independence.
Median (Q1, Q3) depicted. Grey bars indicate normal range. *Erythropoietin data were not collected in Phase 1/2 studies.

Bone marrow histology and myeloid to erythroid ratio improved in Phase 3 patients who achieved TI

Bone marrow assessment post beti-cel infusion

Screening	Month 12	Month 24
		
Hypercellular; M:E 1:5.5	Normocellular; M:E 1:1.3	Normocellular; M:E 1.2:1
		
Hypercellular; M:E 1:2:2	Hypocellular; M:E 1:1:1	Normocellular; M:E 1:2:1

Scale bars: 50 µm.
M:E ratio in healthy individuals[1]: 3-4:1

17/26 TI patients (65%) had normocellular histology at M24

M:E, myeloid to erythroid ratio; TI, transfusion independence.
1. Origa R. GeneReviews®. 2018. https://www.ncbi.nlm.nih.gov/books/NBK1426/ (accessed Jan 10, 2022).

Reduced iron burden in patients who achieved TI







Iron burden was reduced in patients who achieved TI, as shown by cardiac T2*, liver iron concentration, and serum ferritin

LIC, liver iron concentration; TI, transfusion independence. Median (min – max) reported. Patients received iron removal therapy at the discretion of the investigator. Median (Q1, Q3) depicted. Last-observation-carried-forward imputed values are included. Grey bars indicate normal range.

Patients who achieved TI and received iron management therapy

	Phase 1/2 (N=15)	Phase 3 (N=34)	Overall (N=49)
Iron chelation			
Restarted iron chelation, n (%)	15 (100)	22 (64.7)	37 (75.5)
Months to restarting iron chelation, median (min– max)	10.9 (1.7-25)	7.5 (0.8-17.5)	8.2 (0.8-25)
Stopped iron chelation, n (%)	11 (73.3)	10 (29.4)	21 (42.9)
Duration of iron chelation in months, median (min–max)	39.3 (12.6-62.3)	7.9 (0.2-24.6)	24.6 (0.2-62.3)
Phlebotomy			
Received phlebotomy, n (%)	3 (20.0)	9 (26.5)*	12 (24.5)
Months to starting phlebotomy, median (min–max)	20.7 (12.7-31.6)	8.0 (3.2-20.6)	9.8 (3.2-31.6)
Received only phlebotomy, n (%)	3 (20.0)	3 (8.8)	6 (12.2)

76% (37/49) restarted iron chelation and 25% (12/49) received phlebotomy
(6 of whom were also receiving iron chelation)

TI, transfusion independence. *Including 6 patients receiving iron chelation therapy.

PedsQL Scores increased from baseline starting at Month 12 and continued through Month 24 in pediatric patients who achieved TI



Improvements in HRQoL more pronounced for patients who were below the population norm at baseline

HRQoL, health-related quality of life; PedsQL, Pediatric Quality of Life Inventory; TI, transfusion independence.

SF-36 Scores increased from baseline starting at Month 12 and continued through Month 24 in adult patients who achieved TI





Improvements in HRQoL were early and sustained, and more pronounced for patients who were below the population norm at baseline

HRQoL, health-related quality of life; SF-36v, Short Form-36 Health Survey Physical Component Summary and Mental Component Summary Version 2; TI, transfusion independence.

Safety profile after beti-cel infusion

- All patients were alive at last follow-up
- 18% (11/63) of patients experienced ≥1 AE considered related or possibly related to beti-cel
  - All events were grade 1/2 except two events of grade 3 thrombocytopenia (one was serious)
  - No beti-cel-related AEs beyond 2 years post-infusion
- VOD was reported in 11% (7/63) patients
  - 5 patients had serious VOD (3 grade 4; 2 grade 3)
  - 2 patients had non-serious VOD (grade 2)
  - All events resolved
- No malignancies, insertional oncogenesis, or vector-derived replication competent lentivirus
- Polyclonal reconstitution: no single clone meets criteria for clonal predominance*
- Two male patients, one of whom underwent fertility preservation, reported the births of healthy children with their partners

AEs in ≥ 2 patients from infusion to last follow-up	N = 63 n (%)
AEs considered possibly related or related to beti-cel	
Abdominal pain	5 (8)
Thrombocytopenia	3 (5)
Serious AEs	
VOD	5 (8)
Pyrexia	5 (8)
Neutropenia	3 (5)
Thrombocytopenia	3 (5)
Sepsis†	3 (5)
Appendicitis	2 (3)
Febrile neutropenia	2 (3)
Major depression	2 (3)
Stomatitis	2 (3)

AE, adverse event. VOD, veno-occlusive liver disease. *Criteria for clonal predominance for an individual subject is defined as an insertional site-specific vector copy number > 0.5 c/dg, estimating > 50% clonal contribution. †Sepsis events included neutropenic sepsis, bacterial sepsis and sepsis not otherwise specified.

Summary of data from patients treated with beti-cel gene therapy in Phase 1/2 and 3 studies

63 patients treated in 4 clinical studies evaluating safety and efficacy of beti-cel for TDT with genotypes spanning a broad range of TDT severity and across several age groups

One-time beti-cel gene therapy enabled durable TI with up to 7 years follow-up

- Persistent vector-positive hematopoietic cells
- Stable gene therapy-derived HbA, HbA^{T87Q}
- Patients who achieved TI showed early and sustained improvements in HRQoL



Reduction of ineffective erythropoiesis and iron overload in patients who achieved TI

- Soluble transferrin receptor and erythropoietin demonstrated improvement
- Improvement of LIC, serum ferritin, and cardiac T2* toward normal levels

Absence of drug product-related AEs >2 years post-infusion supports a favorable long-term safety profile

- Safety profile consistent with known effects of single-agent busulfan myeloablation
- No vector-derived replication-competent lentivirus or events of insertional oncogenesis or hematologic malignancy reported

beti-cel is a potentially curative gene therapy for patients with TDT through the achievement of durable TI and normal or near-normal Hb levels

AE, adverse event; Hb, hemoglobin; HbA, adult hemoglobin; LIC, liver iron concentration; TDT, transfusion-dependent β-thalassemia; TI, transfusion.

Thank you to the study participants and their families

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA

Children's Hospital of Philadelphia, Philadelphia, PA, USA

UCSF Benioff Children's Hospital, Oakland, CA, USA

bluebird bio, Inc.:

- Gloria Tao
- Shamshad Ali
- Jessica Ward
- Ami Deora
- Heidi Elliot
- Dana Martin
- Kailey Walsh
- Ankit Lodaya

GeneWerk GmbH, Heidelberg, Germany

George Papanikolaou Hospital, Thessaloniki, Greece

Heidelberg University Hospital, Heidelberg, Germany

Hannover Medical School, Hannover, Germany

Hôpital de la Timone, Marseille, France

Hôpital Necker-Enfants Malades, Paris, France

IRCCS Bambino Gesù Children's Hospital, Rome, Italy

University College London Hospital, London, UK

UCL Great Ormond Street Hospital, London, UK

Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Royal Prince Alfred Hospital Camperdown, Australia